trending Market Intelligence /marketintelligence/en/news-insights/trending/N9762nYxRNd2qbH8AEWNrw2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Report: Cerberus seeking buyers for pharmaceutical company Covis

Street Talk - Ep. 64: Coronavirus jumpstarts digital adoption

Street Talk Podcast

Street Talk - Ep. 63: Deal talks continue amid bank M&A freeze, setting up for strong Q4

Street Talk Podcast

Street Talk - Ep. 62: 'Brutal' outlook for oil demand offers banks in oil patch no relief

Amid Q1 APAC Fintech Funding Slump, Payment Companies Drove Investments

Report: Cerberus seeking buyers for pharmaceutical company Covis

Cerberus Capital Management LP is looking to sell private pharmaceutical company Covis Pharma Holdings Sàrl, Bloomberg News reported Oct. 23, citing anonymous sources.

Dutch company Covis manufactures therapies for respiratory, allergy, cardiovascular, gastroenterology and central nervous system diseases.

The New York-based private equity company is working with a financial adviser for the deal, which would be valued at about $800 million.

Other private equity firms have also shown interest in buying Covis, sources told Bloomberg News, adding that a formal sale process is expected to start soon.

Representatives for Cerberus declined to comment, while Covis' representatives did not respond to requests for a comment about the sale, according to Bloomberg News.